Funding for this research was provided by:
This study was funded by AstraZeneca and Amgen Inc.
Received: 5 May 2020
Accepted: 6 September 2020
First Online: 13 October 2020
Ethics approval and consent to participate
: Written, informed consent was obtained from all patients before enrolment into the study. The study was conducted in accordance with the principles established in the Declaration of Helsinki and the International Conference on Harmonisation guidelines for good clinical practice.
: Not applicable.
: MW is an employee of National Jewish Health and has received consulting fees from AstraZeneca, Equillium, Genentech, GlaxoSmithKline, Novartis, Regeneron, Restorbio, Sanofi and Teva. GC, KB, ÅH, GA, TP, TS, EGG and JMG are employees and shareholders of AstraZeneca. PK and MM are employees of Amgen Inc.